Brian Agnew
Life Technologies
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Brian Agnew.
Methods of Molecular Biology | 2011
Courtenay Hart; Lucas G. Chase; Mahbod Hajivandi; Brian Agnew
Human mesenchymal stem cells (hMSCs) are multipotent stem cells that can differentiate into a variety of cell types in vitro including osteoblasts, adipocytes, and chondrocytes. Here we apply a metabolic labeling approach to characterize changes in cellular glycoprotein expression during hMSC differentiation and to identify glycoprotein markers unique to differentiated cell types. The two-step labeling method involves the metabolic incorporation of unnatural azido-modified sugars into protein glycans and subsequent ligation with fluorescent azide-reactive detection probes utilizing the copper (I)-catalyzed cycloaddition reaction between azides and alkynes, or click chemistry. Metabolic labeling of cell surface O-linked or sialic acid-containing glycoproteins, or intracellular O-GlcNAc-modified proteins was accomplished by feeding cells the tetraacetylated azide-modified sugar precursors, GalNAz, ManNAz, or GlcNAz, respectively, for 48-72 h prior to harvesting the cells. The cells were then lysed, and protein extracts were reacted with a fluorescent alkyne detection probe. Labeled glycoproteins were analyzed by 1D and 2D gel electrophoresis and detected by fluorescence imaging. Our results demonstrate highly sensitive labeling of O-linked, sialic acid-containing, and O-GlcNAc modified proteins in all cell types without affecting cell growth or morphology. Selective labeling of sialic acid-containing glycoproteins by ManNAz was validated by loss of labeling following digestion with sialidase A. Significant changes in cellular glycoprotein profiles were seen upon differentiation into different cell types, and several putative glycoprotein markers were identified by MALDI peptide fingerprinting. One of these identified proteins, Galectin 1, is validated and shown for the first time to be posttranslationally modified by O-glycosylation, most likely by O-linked N-acetylglucosamine (O-GlcNAc).
Archive | 2008
Brian Agnew; Kyle Gee; Kapil Kumal; Maura Ford
Archive | 2007
Brian Agnew; Kyle Gee; Tamara G. Nyberg
Archive | 2007
Brian Agnew; Schuyler B. Corry; Kyle Gee
Archive | 2005
Brian Agnew; Kyle Gee
Archive | 2013
Brian Agnew; Robert Aggeler; Hee Chol Kang; Aimei Chen; Kyle Gee
Archive | 2010
Brian Agnew; Chad Pickens; Upinder Singh
The Journal of Nuclear Medicine | 2014
Brian M. Zeglis; Charles B. Davis; Robert Aggeler; Hee-Chol Kang; Aimei Chen; Brian Agnew; Jason S. Lewis
Free Radical Biology and Medicine | 2012
Bhaskar S. Mandavilli; Robert Aggeler; Upinder Singh; Hee Chol Kang; Kyle Gee; Brian Agnew; Michael S. Janes
Archive | 2011
Brian Agnew; Upinder Singh; Scott Grecian